AngioDynamics Oncology Surgery Biz Helps Drive 13% Sales Growth
This article was originally published in The Gray Sheet
Executive Summary
AngioDynamics' sales advanced 13% to $50.1 million in the firm's most recent fiscal quarter, aided by strong growth in its Oncology/Surgery business, the firm reported Oct. 6
You may also be interested in...
AngioDynamics Taps Former CryoCath Chief Keltjens For CEO Slot
Incoming AngioDynamics CEO Jan Keltjens will draw on his 20-plus years of device industry leadership experience, including as former chief exec of CryoCath Technologies, to shepherd "the next level" of growth at the company
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.